The regulatory approval of anamorelin for treatment of cachexia in patients with non‐small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer in Japan: facts and numbers.
Abstract Anamorelin is a ghrelin receptor agonist that can be administered orally and thought to improve cancer cachexia by improving appetite and increasing serum insulin‐like growth factor‐1. Anamorelin was not approved for use in Europe. In contrast, the use of anamorelin for cancer cachexia in f...
Guardat en:
| Autors principals: | , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Wiley
2021-02-01
|
| Col·lecció: | Journal of Cachexia, Sarcopenia and Muscle |
| Accés en línia: | https://doi.org/10.1002/jcsm.12675 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|